You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2025

LOTEMAX SM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lotemax Sm patents expire, and what generic alternatives are available?

Lotemax Sm is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in thirteen countries.

The generic ingredient in LOTEMAX SM is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lotemax Sm

A generic version of LOTEMAX SM was approved as loteprednol etabonate by SENTISS on April 17th, 2019.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOTEMAX SM?
  • What are the global sales for LOTEMAX SM?
  • What is Average Wholesale Price for LOTEMAX SM?
Summary for LOTEMAX SM
Drug patent expirations by year for LOTEMAX SM
Drug Prices for LOTEMAX SM

See drug prices for LOTEMAX SM

Recent Clinical Trials for LOTEMAX SM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Thomas Chester, ODPhase 4
Illinois College of OptometryEarly Phase 1
Dr Salouti Eye Research CenterPhase 4

See all LOTEMAX SM clinical trials

Pharmacology for LOTEMAX SM
Paragraph IV (Patent) Challenges for LOTEMAX SM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LOTEMAX SM Ophthalmic Gel loteprednol etabonate 0.38% 208219 1 2022-11-14

US Patents and Regulatory Information for LOTEMAX SM

LOTEMAX SM is protected by two US patents.

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes 11,534,395 ⤷  Subscribe Y ⤷  Subscribe
Bausch And Lomb Inc LOTEMAX SM loteprednol etabonate GEL;OPHTHALMIC 208219-001 Feb 22, 2019 RX Yes Yes 10,596,107 ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 2 of 2 entries

International Patents for LOTEMAX SM

See the table below for patents covering LOTEMAX SM around the world.

CountryPatent NumberTitleEstimated Expiration
Australia 2016211745 Ophthalmic suspension composition ⤷  Subscribe
European Patent Office 4268850 COMPOSITION DE SUSPENSION OPHTALMIQUE (OPHTHALMIC SUSPENSION COMPOSITION) ⤷  Subscribe
Poland 3470059 ⤷  Subscribe
Poland 3721868 ⤷  Subscribe
South Korea 102538370 ⤷  Subscribe
South Korea 20170105610 안과용 현탁액 조성물 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 6 of 6 entries

LOTEMAX SM Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for LOTEMAX SM

Introduction

LOTEMAX SM, a formulation of loteprednol etabonate ophthalmic gel at 0.38%, has been approved for the treatment of postoperative inflammation and pain following ocular surgery. This article delves into the market dynamics and financial trajectory of LOTEMAX SM, providing insights into its clinical efficacy, market forecast, competitive landscape, and regulatory milestones.

Clinical Efficacy and Safety

LOTEMAX SM has demonstrated significant clinical efficacy in treating postoperative inflammation and pain. In two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies involving 742 subjects, LOTEMAX SM showed a higher percentage of patients achieving complete resolution of anterior chamber cells and grade 0 pain compared to the vehicle group[2][5].

  • Resolution of Anterior Chamber Cells: Studies showed that 73% and 76% of patients treated with LOTEMAX SM achieved complete resolution of anterior chamber cells at day 8, significantly higher than the vehicle group[2].
  • Pain Reduction: Similarly, a higher percentage of patients experienced grade 0 pain at day 8 with LOTEMAX SM compared to the vehicle group[2].

The safety profile of LOTEMAX SM is also favorable, with no treatment-emergent adverse drug reactions occurring in more than 1% of patients. Monitoring of intraocular pressure (IOP) is recommended if the product is used for 10 days or longer[2].

Market Forecast

The market for LOTEMAX SM is expected to grow significantly over the next decade. Here are some key points from the market forecast:

  • Market Expansion: The market for postoperative pain and inflammation is set to expand due to extensive research and increased healthcare spending globally. This expansion will enable drug manufacturers to penetrate the market more effectively[1][4].
  • Forecasted Sales: Detailed analyses of forecasted sales data from 2023 to 2032 indicate a positive trajectory for LOTEMAX SM. These forecasts will help clients in decision-making regarding their therapeutic portfolios[1][4].
  • Competitive Landscape: The market will see competition from other emerging therapies, but LOTEMAX SM's advanced formulation and clinical efficacy are expected to maintain its market position. Late-stage emerging therapies will also impact the market, but LOTEMAX SM's current dominance is likely to continue[1][4].

Competitive Landscape

The competitive landscape for LOTEMAX SM includes both marketed therapies and late-stage emerging therapies.

  • Marketed Therapies: LOTEMAX SM competes with other corticosteroids and anti-inflammatory agents used in postoperative care. However, its submicron particle size and enhanced ocular penetration give it a competitive edge[1][4].
  • Late-stage Emerging Therapies: Several new therapies are in development, focusing on novel approaches to treat postoperative inflammation and pain. These therapies will provide competition but are not expected to immediately surpass LOTEMAX SM's market position[1][4].

Regulatory Milestones

LOTEMAX SM has achieved several regulatory milestones:

  • FDA Approval: LOTEMAX SM was approved by the FDA in 2019 for the treatment of postoperative inflammation and pain following ocular surgery. The approval was based on adequate and well-controlled clinical trials[5].
  • Developmental Activities: The drug has undergone extensive clinical trials, including Phase 3 studies, which have demonstrated its efficacy and safety. Regulatory submissions and approvals have been key in its market entry and expansion[1][4].

SWOT Analysis

A SWOT analysis provides a comprehensive view of LOTEMAX SM's market position:

  • Strengths: Advanced submicron formulation, enhanced ocular penetration, and strong clinical efficacy data.
  • Weaknesses: Potential for increased intraocular pressure if used for extended periods, and the need for ongoing monitoring.
  • Opportunities: Growing market for postoperative care, increasing healthcare spending, and potential for use in a broader range of ocular surgeries.
  • Threats: Emerging therapies and competition from other anti-inflammatory agents[1][4].

Analysts' Views

Analysts view LOTEMAX SM as a significant player in the postoperative care market:

  • Market Dominance: Analysts expect LOTEMAX SM to maintain its market dominance due to its advanced formulation and strong clinical data[1][4].
  • Future Prospects: The launch of late-stage emerging therapies will impact the market, but LOTEMAX SM's current position and ongoing research and development activities are expected to keep it competitive[1][4].

Financial Trajectory

The financial trajectory for LOTEMAX SM is positive, driven by several factors:

  • Sales Growth: Forecasted sales data indicate a steady growth in revenue from 2023 to 2032, driven by increasing market demand and the drug's clinical efficacy[1][4].
  • Market Penetration: The drug's ability to penetrate more into the market due to its advanced formulation and strong safety profile will contribute to its financial success[1][4].

Key Takeaways

  • Clinical Efficacy: LOTEMAX SM has demonstrated strong clinical efficacy in treating postoperative inflammation and pain.
  • Market Forecast: The market for LOTEMAX SM is expected to grow significantly over the next decade.
  • Competitive Landscape: The drug faces competition from emerging therapies but maintains a competitive edge due to its advanced formulation.
  • Regulatory Milestones: LOTEMAX SM has achieved significant regulatory milestones, including FDA approval.
  • Financial Trajectory: The financial outlook for LOTEMAX SM is positive, driven by sales growth and market penetration.

FAQs

  1. What is LOTEMAX SM used for? LOTEMAX SM is used for the treatment of postoperative inflammation and pain following ocular surgery.

  2. What is the unique feature of LOTEMAX SM? LOTEMAX SM has a submicron particle size, which enhances its ocular penetration and residence time in anterior segment tissues.

  3. How does LOTEMAX SM compare to other loteprednol etabonate formulations? LOTEMAX SM provides twice the penetration to the aqueous humor compared to LOTEMAX Gel 0.5% due to its smaller particle size[1].

  4. What are the potential side effects of LOTEMAX SM? The most significant potential side effect is an increase in intraocular pressure if used for extended periods. Monitoring is recommended if the product is used for 10 days or longer[2].

  5. What is the market outlook for LOTEMAX SM? The market outlook is positive, with forecasted sales growth from 2023 to 2032 driven by increasing demand and the drug's clinical efficacy[1][4].

Sources

  1. GlobeNewswire: "United States LOTEMAX SM (Loteprednol Etabonate Ophthalmic Gel) Drug Insight and Market Forecast - 2032"[1].
  2. LOTEMAX SM Official Website: "Proven Efficacy - LOTEMAX SM"[2].
  3. GlobeNewswire: "United States LOTEMAX SM (Loteprednol Etabonate Ophthalmic Gel) Drug Market Insights and Forecast Report 2022-2032"[4].
  4. FDA: "Summary Review - LOTEMAX SM (loteprednol etabonate ophthalmic gel), 0.38%"[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.